Insiders · Profile

Wahl Bryan

General Counsel at Tarsus Pharmaceuticals. Filing since 30 Nov 2022. CIK 0001841401

Company

Date

Role

Action

Shares

Amount

Of holding

TARS Tarsus Pharmaceuticals, Inc.

19 Mar 2026

General Counsel

Sold at will

4,231

$283.48K

6.2%

TARS Tarsus Pharmaceuticals, Inc.

18 Mar 2026

General Counsel

Sold at will

4,125

$283.43K

5.7%

TARS Tarsus Pharmaceuticals, Inc.

17 Mar 2026

General Counsel

Sold at will

4,084

$283.51K

5.3%

TARS Tarsus Pharmaceuticals, Inc.

20 Mar 2025

General Counsel

Sold at will

3,084

$154.54K

5.6%

TARS Tarsus Pharmaceuticals, Inc.

19 Mar 2025

General Counsel

Sold at will

3,261

$154.57K

5.6%

TARS Tarsus Pharmaceuticals, Inc.

18 Mar 2025

General Counsel

Sold at will

3,341

$154.65K

5.4%

TARS Tarsus Pharmaceuticals, Inc.

18 Mar 2024

General Counsel

Sold at will

4,436

$135.74K

9.8%

TARS Tarsus Pharmaceuticals, Inc.

30 Nov 2023

General Counsel

Sold at will

8,356

$136.29K

20.7%

TARS Tarsus Pharmaceuticals, Inc.

23 Mar 2023

General Counsel

Sold at will

371

$4.51K

2.2%

TARS Tarsus Pharmaceuticals, Inc.

22 Mar 2023

General Counsel

Sold at will

357

$4.51K

2.1%

TARS Tarsus Pharmaceuticals, Inc.

21 Mar 2023

General Counsel

Sold at will

350

$4.51K

2.0%

TARS Tarsus Pharmaceuticals, Inc.

20 Mar 2023

General Counsel

Sold at will

357

$4.50K

2.0%

TARS Tarsus Pharmaceuticals, Inc.

17 Mar 2023

General Counsel

Sold at will

339

$4.50K

1.9%

TARS Tarsus Pharmaceuticals, Inc.

16 Mar 2023

General Counsel

Sold, plan not stated

337

$4.53K

1.8%

TARS Tarsus Pharmaceuticals, Inc.

2 Dec 2022

General Counsel

Sold, plan not stated

1,154

$19.50K

7.8%

TARS Tarsus Pharmaceuticals, Inc.

1 Dec 2022

General Counsel

Sold, plan not stated

1,164

$19.50K

7.3%

TARS Tarsus Pharmaceuticals, Inc.

30 Nov 2022

General Counsel

Sold, plan not stated

1,183

$19.52K

6.9%

17 decisions on file.